Kovaxin update: Bharat Biotech’s Kovid vaccine generates ‘strong immune response’ on animals India News


New Delhi: Hyderabad-based vaccine head Bharat Biotech has announced that its Kovid-19 vaccine candidate Kovaxin has developed a “strong immune response” to the highly infectious monovirus during testing on animal rhesus macaques, preventing infection and disease Can go The SARS-CoV-2 virus contains a large amount of primates to live. ”
The tests on the animals, whose detailed results were now made public, were conducted before human trials, which began on 15 July. Under Phase-I human trials, there were 375 volunteers and under Phase-2 trials there were about 1,200 volunteers. Kovaxin shots were given, a source told TOI.
Explaining the testing on animals, Bharat Biotech said on Friday, “A 2-dose vaccination regime of inactive SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (evenly divided into four groups). One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates on days 0 and 14. All maca were exposed to viral challenge 14 days after the second dose. ”
On animal test results, it stated, “The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing virus replication in the nasal cavity, throat, and lung tissue of the monkey. Placebo Unlike the group, no evidence of pneumonia was observed by histopathological examination in the vaccinated groups. Adverse events in animals were not observed in immunized animals with two-dose vaccination. “” These results showed protective efficacy in a live viral challenge model. , “The company tweeted.
In addition, to develop kovaxin in collaboration with NIV-Pune, Bharat Biotech is simultaneously working on the nasal vaccine Coroflu, in collaboration with US researchers at the University of Wisconsin, Madison, against Kovid-19, and to develop human monoclonal antibodies. Is heading the CSIR-approved project. Kovid as therapy for infection.
Each phase of the clinical trial of covaxin is to test its safety and ability to develop an effective immune response. The Phase-I trial focuses on safety and dose determination in a small group of healthy participants, while Phase-II looks at the effectiveness of the vaccine. Phase III, which is yet to begin, will consider these aspects in a much larger population that would represent a broader demographic.
The Serum Institute has stopped trials in India on its vaccine, which is being developed in collaboration with AstraZeneca and the University of Oxford, following a study in the UK about the disease, leading to the race for the development of the indigenous Kovid vaccine to covaxin is believed.
In the video: Animal testing of covaxin elicits strong immune response, says Bharat Biotech

.